AstraZeneca licenses Starpharma's drug delivery platform

AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound on signature, and with potential for follow on compounds directed at a defined family of targets. Under the agreement Starpharma will receive a signature payment of US$2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP product of USD$124 million (A$177 million).